HU229909B1 - Use of paclitaxel stabilized with albumin for the preparation of a drug for the treatmentof solid tumors and the drug obtained thereby - Google Patents

Use of paclitaxel stabilized with albumin for the preparation of a drug for the treatmentof solid tumors and the drug obtained thereby Download PDF

Info

Publication number
HU229909B1
HU229909B1 HU0102039A HUP0102039A HU229909B1 HU 229909 B1 HU229909 B1 HU 229909B1 HU 0102039 A HU0102039 A HU 0102039A HU P0102039 A HUP0102039 A HU P0102039A HU 229909 B1 HU229909 B1 HU 229909B1
Authority
HU
Hungary
Prior art keywords
drug
solid tumors
microparticles
treatment
concentration
Prior art date
Application number
HU0102039A
Other languages
English (en)
Hungarian (hu)
Inventor
Marco Falciani
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU229909(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of HU0102039D0 publication Critical patent/HU0102039D0/hu
Publication of HUP0102039A2 publication Critical patent/HUP0102039A2/hu
Publication of HUP0102039A3 publication Critical patent/HUP0102039A3/hu
Publication of HU229909B1 publication Critical patent/HU229909B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0102039A 2000-05-18 2001-05-17 Use of paclitaxel stabilized with albumin for the preparation of a drug for the treatmentof solid tumors and the drug obtained thereby HU229909B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Publications (4)

Publication Number Publication Date
HU0102039D0 HU0102039D0 (en) 2001-07-30
HUP0102039A2 HUP0102039A2 (hu) 2002-05-29
HUP0102039A3 HUP0102039A3 (en) 2002-12-28
HU229909B1 true HU229909B1 (en) 2014-12-29

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102039A HU229909B1 (en) 2000-05-18 2001-05-17 Use of paclitaxel stabilized with albumin for the preparation of a drug for the treatmentof solid tumors and the drug obtained thereby

Country Status (22)

Country Link
US (1) US6652884B2 (https=)
EP (1) EP1155692B1 (https=)
JP (1) JP2001354559A (https=)
KR (2) KR20010105248A (https=)
CN (1) CN1198609C (https=)
AT (1) ATE267594T1 (https=)
AU (1) AU781517B2 (https=)
BR (1) BR0102040A (https=)
CA (1) CA2345482A1 (https=)
DE (1) DE60103453T2 (https=)
DK (1) DK1155692T3 (https=)
ES (1) ES2221874T3 (https=)
HU (1) HU229909B1 (https=)
IL (1) IL142674A0 (https=)
IT (1) ITMI20001107A1 (https=)
MX (1) MXPA01004980A (https=)
NO (1) NO330511B1 (https=)
NZ (1) NZ511201A (https=)
PT (1) PT1155692E (https=)
RU (1) RU2270003C2 (https=)
TR (1) TR200101353A3 (https=)
ZA (1) ZA200103755B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
CA2509365C (en) * 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0617663A2 (pt) * 2005-10-21 2011-08-02 Panacea Biotec Ltd composições aperfeiçoadas para terapia de cáncer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
JP6387389B2 (ja) * 2013-03-13 2018-09-05 アブラクシス バイオサイエンス， エルエルシー 小児充実性腫瘍の処置の方法
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
WO2018037595A1 (ja) 2016-08-26 2018-03-01 哲治 奥野 微小血管血流低減剤およびその利用
TWI660728B (zh) 2018-02-09 2019-06-01 National Chiao Tung University 胺基喹唑啉衍生物及其醫藥組合物與用途
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
CN120919082A (zh) * 2025-10-16 2025-11-11 天津医科大学总医院 一种负载蛋白药物的GelMA微球、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
CA2362338A1 (en) 1998-07-30 2000-02-10 Human Rt. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin

Also Published As

Publication number Publication date
RU2270003C2 (ru) 2006-02-20
NO330511B1 (no) 2011-05-09
PT1155692E (pt) 2004-09-30
CN1324613A (zh) 2001-12-05
EP1155692B1 (en) 2004-05-26
HUP0102039A2 (hu) 2002-05-29
ES2221874T3 (es) 2005-01-16
TR200101353A2 (tr) 2001-12-21
DE60103453D1 (de) 2004-07-01
JP2001354559A (ja) 2001-12-25
AU781517B2 (en) 2005-05-26
CA2345482A1 (en) 2001-11-18
HUP0102039A3 (en) 2002-12-28
US6652884B2 (en) 2003-11-25
HK1040368A1 (en) 2002-06-07
MXPA01004980A (es) 2002-08-06
TR200101353A3 (tr) 2001-12-21
NO20012409L (no) 2001-11-19
ITMI20001107A0 (it) 2000-05-18
BR0102040A (pt) 2002-03-19
ITMI20001107A1 (it) 2001-11-18
CN1198609C (zh) 2005-04-27
AU3876501A (en) 2001-11-22
NZ511201A (en) 2002-11-26
ATE267594T1 (de) 2004-06-15
US20010046961A1 (en) 2001-11-29
HU0102039D0 (en) 2001-07-30
IL142674A0 (en) 2002-03-10
EP1155692A1 (en) 2001-11-21
DK1155692T3 (da) 2004-08-09
KR20080091747A (ko) 2008-10-14
KR20010105248A (ko) 2001-11-28
NO20012409D0 (no) 2001-05-16
ZA200103755B (en) 2001-11-15
DE60103453T2 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
HU229909B1 (en) Use of paclitaxel stabilized with albumin for the preparation of a drug for the treatmentof solid tumors and the drug obtained thereby
van den Berge et al. Intracavitary brachytherapy of cystic craniopharyngiomas
Pollack et al. Stereotaxic intracavitary irradiation for cystic craniopharyngiomas
Seidlin et al. Radioiodine therapy of metastases from carcinoma of the thyroid: a six-year progress report
HU226897B1 (en) Radiopharmacological compositions and process for producing and administering them
US20070196277A1 (en) Compositions and Methods for the Direct Therapy of Tumors
Cameron et al. A long-term follow-up of synovial sarcoma
Deppe et al. Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate
White et al. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-9963) in dogs
Prvulovich et al. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases
Sheline et al. Studies with Radioiodine: VI. Evaluation of Radioiodine Treatment of Carcinoma of the Thyroid Based on the Experience at the University of California from 1938 to 1954
Toftdahl et al. Dynamic cholescintigraphy: induction and description of gallbladder emptying
US20210330644A1 (en) Combination therapy for treating metastatic prostate cancer
De Lathouwer et al. Sarcoma arising in irradiated jawbones. Possible relationship with previous non-malignant bone lesions: Report of 6 cases and review of the literature
Aggarwal Clinical Case Reports
Lee et al. Intradiploic epidermoid cyst in a dog
Niewiarowski et al. Feline cholescintigraphy: studies on role of cholecystokinin in regulation of gallbladder function
EP0254313B1 (en) Use of ketamine for the manufacturing of medicaments for prevention or reduction of the effects of stroke in a subject having increased risk for stroke
EP1413313A1 (en) DIAGNOSIS AND TREATMENT OF INSULIN−DEPENDENT DIABETES MELLITUS AND INSULITIS
Singh A case report on the rare presentation of aneurysmal bone cyst on proximal radius with management
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌
WO2026021460A1 (zh) 治疗前列腺癌的方法
AU2008255204B2 (en) Medicaments for chemotherapeutic treatment of disease
Cotrina-Monroy et al. Notification of an adverse effect to human albumin 99MTc-nanocolloid
JP2026501344A (ja) 新規な溶液

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ABRAXIS BIOSCIENCE, INC., US

Free format text: FORMER OWNER(S): ACS DOBFAR S.P.A., IT

GB9A Succession in title

Owner name: ABRAXIS BIOSCIENCE, LLC, US

Free format text: FORMER OWNER(S): ACS DOBFAR S.P.A., IT; ABRAXIS BIOSCIENCE, INC., US

HC9A Change of name, address

Owner name: ABRAXIS BIOSCIENCE, LLC, US

Free format text: FORMER OWNER(S): ACS DOBFAR S.P.A., IT; ABRAXIS BIOSCIENCE, INC., US; ABRAXIS BIOSCIENCE, LLC, US